"In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 trial of tibulizumab in SSc. We’ve worked closely with our contract research organization (CRO) to begin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback